AstraZeneca - Articles and news items

AstraZeneca to cut a further 7,300 jobs

Industry news, News / 2 February 2012 / AstraZeneca

In conjunction with the publication of its full year 2011 results earlier today, AstraZeneca announced new restructuring initiatives designed to improve productivity and strengthen the company’s commercial, operations and research and development capabilities.

(more…)

AstraZeneca and Bristol-Myers Squibb receive complete response letter from US FDA for dapagliflozin

Industry news, News / 19 January 2012 / AstraZeneca

AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapagliflozin for the treatment of type 2 diabetes in adults.

(more…)

AstraZeneca and IMS Health announce real-world evidence collaboration in Europe

Industry news, News / 11 January 2012 / AstraZeneca

AstraZeneca today announced that it has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.

(more…)

AstraZeneca reaffirms December 2011 financial guidance for 2011 and mid-term planning assumptions for the 2010 to 2014 period

Industry news, News / 9 January 2012 / AstraZeneca

During a routine consensus collection process, confidential Company information was inadvertently embedded in a spreadsheet template sent to the sell-side analyst community that follows the Company. This information is out of date planning information, and does not represent the Company’s view of expected financial performance for the full year 2011 or for future periods.

(more…)

AstraZeneca updates on olaparib and TC-5214 development programmes

Industry news, News / 20 December 2011 / AstraZeneca

AstraZeneca has announced that its investigational compound olaparib will not progress into Phase III development for the maintenance treatment of serous ovarian cancer. In addition, AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with major depressive disorder did not meet its primary end point. As a result, AstraZeneca will take pre-tax impairment charges totalling $381.5 million to R&D expense in the fourth quarter of 2011. The company confirms its expectation for full year Core EPS in the range of $7.20 to $7.40, but with the inclusion of these intangible impairments, Core EPS is likely to be in the lower half of this range. (more…)

G-BA issues positive final medical benefit assessment for BRILIQUE in Germany

Industry news, News / 15 December 2011 / AstraZeneca

AstraZeneca today announced that the German assessment body, the Federal Joint Committee (G-BA), has issued its final decision regarding the medical benefit of BRILIQUE (ticagrelor). This positive decision is in line with the preliminary assessment published by the Institute for Quality and Efficiency in Healthcare (IQWiG) in October, with the addition of a new ST-Elevation Myocardial Infarction/Percutaneous Coronary Intervention (STEMI/PCI) sub-group for patients over 75 years or patients with prior stroke or transient ischemic attack (TIA).

(more…)

AstraZeneca to acquire generics company to broaden patient access to medicines in China

Industry news, News / 8 December 2011 / AstraZeneca

AstraZeneca today announced it has entered into an agreement to acquire Guangdong BeiKang Pharmaceutical Company Ltd, a privately-owned generics manufacturing company, based in Conghua City, Guangdong province, China. The deal will give AstraZeneca access to a portfolio of injectable medicines used to treat infections which AstraZeneca will make available to patients in China.

(more…)

AstraZeneca to streamline US sales organisation

Industry news, News / 8 December 2011 / AstraZeneca

AstraZeneca announced today that it will reduce its US sales force by approximately 1,150 leadership positions and sales representatives as part of the company’s ongoing strategy to operate its business more efficiently to best serve patients in the US. (more…)

Groundbreaking scientific collaboration gives UK academia access to compounds to advance medical research

Industry news, News / 5 December 2011 / AstraZeneca

A wide range of compounds will be made available free of charge to UK medical researchers next year, following a landmark agreement between the Medical Research Council (MRC) and AstraZeneca. In a new type of collaboration, academia will be granted access to 22 compounds, developed by AstraZeneca. Through MRC funding, UK academia will conduct studies to better understand what drives a range of diseases with a view to exploring new treatment opportunities.

(more…)

KOMBOGLYZE™ receives marketing authorisation in the European Union for adult patients with Type 2 diabetes

Industry news, News / 29 November 2011 / AstraZeneca

AstraZeneca and Bristol-Myers Squibb Company announced today that the European Commission has granted marketing authorisation for KOMBOGLYZE™ (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European Union.

(more…)

ONGLYZA® (saxagliptin) approved for use in Europe as combination therapy with insulin in adults with type 2 diabetes

Industry news, News / 28 November 2011 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the European Commission has approved ONGLYZA® (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.

(more…)

AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures

Industry news, News / 28 November 2011 / AstraZeneca

AstraZeneca today announced that it has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. MedImmune Ventures is an evergreen venture capital fund that focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.

(more…)